brand logo

Am Fam Physician. 2023;108(1):93-94

Author disclosure: No relevant financial relationships.

DrugDosageDose formCost*
Tirzepatide (Mounjaro)2.5 mg subcutaneously once weekly for four weeks, followed by 5 mg once weeklyInjection pen (pre-filled single-dose pen, 0.5 mL): 2.5, 5, 7.5, 10, 12.5, and 15 mg$1,000 for four 2.5-mg injection pens
Titration: increase dosage by 2.5 mg every four weeks to a maximum dosage of 15 mg once weekly if additional glycemic control is needed

Tirzepatide (Mounjaro) is labeled for the treatment of type 2 diabetes mellitus in adults as an adjunct to lifestyle modifications. It is the first agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptors.1 This dual effect is hypothesized to impact glycemic control and weight loss more than GLP-1 receptor agonism alone due in part to the prevalence of glucose-dependent insulinotropic polypeptide receptors in adipose tissue and the brain.

Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at

Continue Reading

More in AFP

More in PubMed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.